parallel

Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints

SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…

3 weeks ago

SciSparc: AutoMaxs Shareholders Approve Merger with SciSparc

TEL AVIV, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage…

1 month ago

Three years to go: LA28 competition schedule revealed as PlayLA programme surpasses one million registrations

15 July 2025 - With three years to go until the Opening Ceremony of the LA28 Olympic Games, the Organising Committee has…

3 months ago